Previous 10 | Next 10 |
2024-06-06 20:00:08 ET Corinne Jenkins from Goldman Sachs issued a price target of $44.00 for HALO on 2024-06-06 18:10:00. The adjusted price target was set to $44.00. At the time of the announcement, HALO was trading at $51.44. The overall price target consensus is at $...
2024-06-06 19:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for HALO on June 6, 2024 06:10PM ET. The previous analyst recommendation was Neutral. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
2024-06-06 12:51:08 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...
A look at the top 10 most actives in the United States Nauticus Robotics Inc. (KITT) rose 29.5% to $0.1787 on volume of 92,016,620 shares Freight Technologies Inc. (FRGT) rose 92.0% to $1.2 on volume of 65,878,105 shares Aethlon Medical Inc. (AEMD) rose 68.2% to $0.7379 on volume of 48,98...
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook PR Newswire Company Granted New European Patent for ENHANZE ® Drug Delivery Platform SAN DIEGO , June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASD...
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform PR Newswire Conference Call Scheduled for Thursday, June 6 at 5:30am PT / 8:30am ET SAN DIEGO , June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc...
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief exec...
2024-05-21 13:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-21 07:29:59 ET More on Bristol-Myers Squibb Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Bristol-Myer...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...
2024-06-07 07:15:04 ET H.C. Wainwright analyst issues BUY recommendation for HALO on June 7, 2024 06:06AM ET. The previous analyst recommendation was Buy. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...